BioCorRx Inc.

Equities

BICX

US09073C2052

Healthcare Facilities & Services

Market Closed - OTC Markets Other stock markets 17:57:49 28/05/2024 BST			5-day change	1st Jan Change
0.73 ^USD	-6.41%		-8.75%	-6.41%

04-03	BioCorRx Inc. Announces Board Resignations	CI
04-01	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 16, 2022 at 04:49 pm

BioCorRx Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 0.020518 million compared to USD 0.010124 million a year ago. Net loss was USD 0.94444 million compared to USD 1.58 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.26 a year ago.

Latest news about BioCorRx Inc.

BioCorRx Inc. Announces Board Resignations	04-03	CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors	02-08	CI
BioCorRx Inc. Announces President Changes	01-05	CI
BioCorRx Inc. announced that it has received $0.2 million in funding	12-07	CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
BioCorRx Inc. announced that it has received $0.2 million in funding	11-09	CI
Biocorrx Inc. Announces Management Changes	11-02	CI
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15/08/23	CI
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Insider Buy: Biocorrx	05/04/23	MT
BioCorRx Inc. announced that it has received $0.299983 million in funding	03/04/23	CI
BioCorRx Inc. announced that it has received $0.599536 million in funding	02/04/23	CI
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
BioCorRx Inc. announced that it expects to receive $0.599536 million in funding	28/03/23	CI
BioCorRx Inc. Announces Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial At 4Th Annual NIH HEAL Initiative Investigator Meeting	07/03/23	CI
BioCorRx Inc. Appoints Harsha Murthy as A Member of the Board of Directors	23/01/23	CI
BioCorRx Inc. Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder, Which is Being Developed Under BioCorRx Pharmaceuticals, Inc	19/01/23	CI
BioCorRx Inc. Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States	07/12/22	CI
BioCorRx Inc. agreed to Spin-Off BioCorRx Pharmaceuticals, Inc.	21/11/22	CI
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
BioCorRx Inc. Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104	13/10/22	CI
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI

Chart BioCorRx Inc.

Duration

Period

More charts

Company Profile

BioCorRx Inc., through its subsidiaries, develops and provides addiction treatment solutions for the treatment of substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. The Company, through its subsidiary, BioCorRx Pharmaceuticals Inc., is engaged in the development of BICX104, a subcutaneous implantable naltrexone pellet for the treatment of both opioid and alcohol use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.

Sector

Healthcare Facilities & Services

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
BIOCORRX INC.	-6.41%	7.02M
HCA HEALTHCARE, INC.	+17.73%	83.46B
CVS HEALTH CORPORATION	-32.08%	67.33B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-3.24%	25.66B
FRESENIUS SE & CO. KGAA	+4.13%	17.91B
LABCORP HOLDINGS INC.	-13.68%	16.54B
QUEST DIAGNOSTICS INCORPORATED	+0.75%	15.43B
NATERA, INC.	+74.92%	13.46B
TENET HEALTHCARE CORPORATION	+73.16%	12.78B
REDE D'OR SÃO LUIZ S.A.	-2.02%	12.33B

Other Healthcare Facilities & Services